MedTrace Logo

T-VEC in Non-melanoma Skin Cancer

NCT03458117 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-03-18

No results posted yet for this study

Summary

Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.

Conditions

Interventions

GENETIC

Talimogene Laherparepvec (T-VEC)

a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Reinhard Dummer, Prof. Dr. · vice-director dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-19
Primary Completion
2022-02-04
Completion
2022-03-15

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458117 on ClinicalTrials.gov